Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | HSD17B3 | P37058 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139595 | 0.88 | HSD17B3 (0.52) | HTTHSD17B3KDM4EALDH1A1MEN1 | |
| SCHEMBL27712176 | 0.84 | HTT (0.50) | HTTHSD17B3ALDH1A1FFAR1PLA2G2A | |
| SCHEMBL8990156 | 0.83 | NOS2 (0.60) | HTTHSD17B3KDM4EALDH1A1 | |
| SCHEMBL27785889 | 0.83 | HSD17B3 (0.57) | HTTHSD17B3FFAR1PLA2G2APLA2G5 | |
| SCHEMBL9603187 | 0.82 | HTT (0.73) | HTTHSD17B3KDM4ENAAAALDH1A1 | |
| SCHEMBL9601564 | 0.82 | HTT (0.73) | HTTHSD17B3KDM4ENAAAALDH1A1 | |
| SCHEMBL9603015 | 0.82 | HTT (0.73) | HTTHSD17B3KDM4ENAAAALDH1A1 | |
| SCHEMBL11298470 | 0.82 | HTT (0.73) | HTTHSD17B3KDM4ENAAAALDH1A1 | |
| SCHEMBL14261445 | 0.82 | HTT (0.73) | HTTHSD17B3KDM4ENAAAALDH1A1 | |
| SCHEMBL10748798 | 0.81 | NOS2 (0.59) | HTTHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608049-B2 | Indazoles | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-19 | — | — | US | disclosed |
| EP-1324987-A1 | INDAZOLES WITH THYROID HORMON LIKE ACTIVITY, A PROCESS FOR ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS | Bayer Aktiengesellschaft (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-20020193610-A1 | Indazoles | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | US | disclosed |
| WO-2002022586-A1 | INDAZOLES HAVING AN ACTION SIMILAR TO THAT OF A THYROID HORMONE, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN MEDICAMENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193610-A1 | Indazoles | CYP3A43, CYP3A5, CYP3A4 | HTT 3227/4885HSD17B3 284/4885KDM4E 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.